Epithalon Reference

Educational, not medical advice reference for Epithalon: Longevity; regulatory status, evidence posture, source review, and schedule notes. Also…

Plain English

What it is
Epithalon (also spelled Epitalon) is a man-made peptide, which is a short chain of amino acids. It is not an FDA-approved medicine. It is sold and talked about as a research chemical, mostly by people interested in longevity and anti-aging.
What people use it for
Fans in the longevity community use it hoping to slow aging, sleep more deeply, and feel younger over time. These hopes come from community reports and older Russian aging research, not from approval to treat any disease.
What the science shows
Most of the evidence comes from animal studies. In one mouse study it lengthened lifespan and lowered breast tumor rates. Much of the human research used an older pineal-gland preparation called epithalamin rather than the modern peptide, and independent Western studies are thin.
The catch
It is not approved to treat anything, and it is not the same product as the human research often cited for it. The FDA has not approved Epithalon and is set to review it for possible compounding use in July 2026. Because these vials are not regulated medicines, product quality and measuring mistakes are real concerns.

Reference summary

Most evidence is preclinical. Human follow-up publications often involve epithalamin or older Russian geroprotector programs rather than contemporary independent epitalon trials.

Regulatory and posture

Categories
Longevity
Aliases
Epitalon, AEDG peptide, Epithalamin-related tetrapeptide
Evidence posture
translational - Human literature is older, indirect, and not the same as modern vial products.
Regulatory status
No FDA-approved Epithalon drug label. Epitalon sits in FDA's table of bulk drug substances previously in Category 2 whose nominations were withdrawn. It is not on the 503A Bulks List and is not permitted for 503A pharmacy compounding. At the July 24, 2026 Pharmacy Compounding Advisory Committee meeting the committee narrowly recommended it for inclusion, against FDA's own reviewers; that recommendation does not bind FDA and changes nothing unless and until FDA completes rulemaking.
Content review status
research reference

Selected public sources

Related tools

For research and educational purposes only. Not medical advice.